Dr. Xiu on HR Expression in Uterine Carcinosarcoma

Joanne Xiu, PhD
Published: Monday, May 04, 2015



Joanne Xiu, PhD, research scientist, Caris Life Sciences, discusses findings from a study that showed hormone receptor (HR) expression is present in a subset of patients with uterine carcinosarcoma.

A study led by Xiu demonstrated that HR is overexpressed in a small subset of patients with uterine carcinosarcoma. Hormonal therapies have not been tested within this tumor type, Xiu explains. This prompts a thought that, following other treatment options, oncologists could consider hormonal therapies for patients.

Moreover, researchers saw the PI3K mTOR pathway activated, suggesting that oncologists could consider a combination of hormonal and targeted therapies. This is something to be tested in clinical trials, Xiu adds.

PD-1/PD-L1 expression was also found in this patient subset.


Joanne Xiu, PhD, research scientist, Caris Life Sciences, discusses findings from a study that showed hormone receptor (HR) expression is present in a subset of patients with uterine carcinosarcoma.

A study led by Xiu demonstrated that HR is overexpressed in a small subset of patients with uterine carcinosarcoma. Hormonal therapies have not been tested within this tumor type, Xiu explains. This prompts a thought that, following other treatment options, oncologists could consider hormonal therapies for patients.

Moreover, researchers saw the PI3K mTOR pathway activated, suggesting that oncologists could consider a combination of hormonal and targeted therapies. This is something to be tested in clinical trials, Xiu adds.

PD-1/PD-L1 expression was also found in this patient subset.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x